Literature DB >> 30033398

Clinical applications of population pharmacokinetic models of antibiotics: Challenges and perspectives.

Femke de Velde1, Johan W Mouton2, Brenda C M de Winter3, Teun van Gelder4, Birgit C P Koch4.   

Abstract

Because of increasing antimicrobial resistance and the shortage of new antibiotics, there is a growing need to optimize the use of old and new antibiotics. Modelling of the pharmacokinetic/pharmacodynamic (PK/PD) characteristics of antibiotics can support the optimization of dosing regimens. Antimicrobial efficacy is determined by susceptibility of the drug to the microorganism and exposure to the drug, which relies on the PK and the dose. Population PK models describe relationships between patients characteristics and drug exposure. This article highlights three clinical applications of these models applied to antibiotics: 1) dosing evaluation of old antibiotics, 2) setting clinical breakpoints and 3) dosing individualization using therapeutic drug monitoring (TDM). For each clinical application, challenges regarding interpretation are discussed. An important challenge is to improve the understanding of the interpretation of modelling results for good implementation of the dosing recommendations, clinical breakpoints and TDM advices. Therefore, also background information on PK/PD principles and approaches to analyse PK/PD data are provided.
Copyright © 2018 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Amikacin (CID: 37768); Amoxicillin (CID: 33613); Anti-bacterial agents; Cefotaxime (CID: 2632); Ceftazidime (CID: 5481173); Ciprofloxacin (CID: 2764); Gentamicin (CID: 3467); Individualized dosing; Levofloxacin (CID: 149096); PK/PD; Population pharmacokinetics; Therapeutic drug monitoring; Tobramycin (CID: 36294); Vancomycin (CID: 14969)

Mesh:

Substances:

Year:  2018        PMID: 30033398     DOI: 10.1016/j.phrs.2018.07.005

Source DB:  PubMed          Journal:  Pharmacol Res        ISSN: 1043-6618            Impact factor:   7.658


  37 in total

1.  Improving Therapeutic Decisions: Pharmacodynamic Monitoring as an Integral Part of Therapeutic Drug Monitoring.

Authors:  Maria Shipkova; Uwe Christians
Journal:  Ther Drug Monit       Date:  2019-04       Impact factor: 3.681

2.  Can Population Pharmacokinetics of Antibiotics be Extrapolated? Implications of External Evaluations.

Authors:  Yu Cheng; Chen-Yu Wang; Zi-Ran Li; Yan Pan; Mao-Bai Liu; Zheng Jiao
Journal:  Clin Pharmacokinet       Date:  2021-01       Impact factor: 6.447

3.  Antibiotics in Adult Cystic Fibrosis Patients: A Review of Population Pharmacokinetic Analyses.

Authors:  Mehdi El Hassani; Jean-Alexandre Caissy; Amélie Marsot
Journal:  Clin Pharmacokinet       Date:  2021-01-15       Impact factor: 6.447

4.  Model-Informed Therapeutic Drug Monitoring of Meropenem in Critically Ill Patients: Improvement of the Predictive Ability of Literature Models with the PRIOR Approach.

Authors:  Anna Chan Kwong; Amaury O'Jeanson; Sonia Khier
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2021-04-08       Impact factor: 2.441

Review 5.  Towards Personalized Antithrombotic Treatments: Focus on P2Y12 Inhibitors and Direct Oral Anticoagulants.

Authors:  Jean Terrier; Youssef Daali; Pierre Fontana; Chantal Csajka; Jean-Luc Reny
Journal:  Clin Pharmacokinet       Date:  2019-12       Impact factor: 6.447

Review 6.  Voriconazole: A Review of Population Pharmacokinetic Analyses.

Authors:  Changcheng Shi; Yubo Xiao; Yong Mao; Jing Wu; Nengming Lin
Journal:  Clin Pharmacokinet       Date:  2019-06       Impact factor: 6.447

7.  Time above the MIC of Piperacillin-Tazobactam as a Predictor of Outcome in Pseudomonas aeruginosa Bacteremia.

Authors:  Elias Tannous; Shelly Lipman; Antonella Tonna; Emma Hector; Ziad Hussein; Michal Stein; Sharon Reisfeld
Journal:  Antimicrob Agents Chemother       Date:  2020-07-22       Impact factor: 5.191

8.  External evaluation of published population pharmacokinetic models of polymyxin B.

Authors:  Ya-Qian Li; Kai-Feng Chen; Jun-Jie Ding; Hong-Yi Tan; Nan Yang; Ya-Qi Lin; Cui-Fang Wu; Yue-Liang Xie; Guo-Ping Yang; Jing-Jing Liu; Qi Pei
Journal:  Eur J Clin Pharmacol       Date:  2021-08-03       Impact factor: 2.953

Review 9.  Aminoglycosides in the Intensive Care Unit: What Is New in Population PK Modeling?

Authors:  Alexandre Duong; Chantale Simard; Yi Le Wang; David Williamson; Amélie Marsot
Journal:  Antibiotics (Basel)       Date:  2021-04-29

10.  Optimal control for colistin dosage selection.

Authors:  Aline Vidal Lacerda Gontijo; André V G Cavalieri
Journal:  J Pharmacokinet Pharmacodyn       Date:  2021-06-22       Impact factor: 2.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.